MT-ND4L — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Auraptene (SCHEMBL2535029)	1.00	5/20
Auraptene (SCHEMBL2535034)	1.00	5/20
SCHEMBL8491443	0.56	4/20
SCHEMBL8489900	0.52	4/20
SCHEMBL8489907	0.52	4/20
SCHEMBL8492838	0.52	4/20
SCHEMBL8492845	0.52	4/20
SCHEMBL8489902	0.51	4/20
SCHEMBL8489908	0.51	4/20
SCHEMBL8491154	0.51	4/20
SCHEMBL8491160	0.51	4/20
SCHEMBL8491619	0.50	4/20
SCHEMBL8491624	0.50	4/20
SCHEMBL8491634	0.50	4/20
7-Prenyloxycoumarin (SCHEMBL4898255)	0.79	3/20
SCHEMBL712741	0.57	3/20
Geiparvarin (SCHEMBL2532495)	0.56	3/20
SCHEMBL6267768	0.55	3/20
SCHEMBL8493191	0.55	3/20
SCHEMBL8493327	0.55	3/20

Clinical trials — most relevant to MT-ND4L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease	PHASE3	COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation	PHASE3	COMPLETED
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease	PHASE2	COMPLETED
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients	PHASE2	RECRUITING
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults	EARLY_PHASE1	COMPLETED
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases	nan	RECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection	nan	COMPLETED
Calf Muscle Strength in Mitochondrial Diseases	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
Diagnostic Odyssey Survey 2	nan	COMPLETED
Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.	nan	UNKNOWN
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Survey on Supplement Use in Mitochondrial Disease	nan	COMPLETED
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months	nan	UNKNOWN
Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
mtDNA Mutation Load Analysis in Mesoangioblasts	nan	RECRUITING
Mitoquines in COPD	nan	UNKNOWN
Natural History in Primary Mitochondrial Myopathies	nan	RECRUITING
Natural History Study of Mitochondrial Myopathy	nan	RECRUITING
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Natural History Study - Mitochondrial Disease	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MT-ND4L binder may also engage these)

Protein	Name	Similarity
Q34572	—	1.000	Q34572 →
Q37809	—	1.000	Q37809 →
O21787	—	1.000	O21787 →
Q35588	—	1.000	Q35588 →
P56632	—	1.000	P56632 →
Q15GS3	—	0.999	Q15GS3 →
Q072K5	—	0.997	Q072K5 →
Q9MEI2	—	0.996	Q9MEI2 →
Q7HLD2	—	0.996	Q7HLD2 →
Q5I195	—	0.996	Q5I195 →
Q5BU90	—	0.995	Q5BU90 →
P61795	—	0.995	P61795 →
Q7YBC1	—	0.995	Q7YBC1 →
O79435	—	0.995	O79435 →
Q7IVV2	—	0.995	Q7IVV2 →
Q2V0A4	—	0.995	Q2V0A4 →
Q9B1C5	—	0.994	Q9B1C5 →
Q7IVV3	—	0.994	Q7IVV3 →
Q70RM6	—	0.994	Q70RM6 →
Q69B84	—	0.993	Q69B84 →
Q9B996	—	0.993	Q9B996 →
Q3LR84	—	0.992	Q3LR84 →
P61796	—	0.992	P61796 →
Q9B987	—	0.992	Q9B987 →
Q3L6Z6	—	0.992	Q3L6Z6 →
Q9B985	—	0.991	Q9B985 →
Q9XMJ3	—	0.991	Q9XMJ3 →
O78754	—	0.991	O78754 →
Q5Y4Q2	—	0.990	Q5Y4Q2 →
Q9ZZY3	—	0.990	Q9ZZY3 →